EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The zymogenic form of SARS-CoV-2 main protease: A discrete target for drug discovery

Pavel Novotný, Jana Humpolíčková, Veronika Nováková, Stancho Stanchev, Kvido Stříšovský, Michala Zgarbová, Jan Weber, Robin Kryštůfek, Jana Starková, Martin Hradilek, Adéla Moravcová, Jana Günterová und 4 weitere

Journal of Biological Chemistry · 2025-01 · 301 (1) · 108079

DOI: 10.1016/j.jbc.2024.108079 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025-01. Verfasst von Pavel Novotný und 15 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic; Faculty of Science, Department of Physical …. Hauptthemen laut MEDLINE: Coronavirus 3C Proteases, SARS-CoV-2, Drug Discovery, Protease Inhibitors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro) autocatalytically releases itself out of the viral polyprotein to form a fully active mature dimer in a manner that is not fully understood. Here, we introduce several tools to help elucidate differences between cis (intramolecular) and trans (intermolecular) proteolytic processing and to evaluate inhibition of precursor Mpro. We found that many mutations at the P1 position of the N-terminal autoprocessing site do not block cis autoprocessing but do inhibit trans processing. Notably, substituting the WT glutamine at the P1 position with isoleucine retains Mpro in an unprocessed precursor form that can be purified and further studied. We also developed a cell-based reporter assay suitable for compound library screening and evaluation in HEK293T cells. This assay can detect both overall Mpro inhibition and the fraction of uncleaved precursor form of Mpro through separable fluorescent signals. We observed that inhibitory compounds preferentially block mature Mpro. Bofutrelvir and a novel compound designed in-house showed the lowest selectivity between precursor and mature Mpro, indicating that inhibition of both forms may be possible. Additionally, we observed positive modulation of precursor activity at low concentrations of inhibitors. Our findings help expand understanding of the SARS-CoV-2 viral life cycle and may facilitate development of strategies to target precursor form of Mpro for inhibition or premature activation of Mpro.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronavirus 3C ProteasesSARS-CoV-2Drug DiscoveryProtease InhibitorsAntiviral AgentsCOVID-19 Drug TreatmentHumansHEK293 CellsCOVID-19Mutation

Stichwörter der Autor:innen

Förster resonance energy transfer (FRET)SARS-CoV-2 main proteaseactivationautoprocessingcell-based assayfluorescence cross-correlation spectroscopy (FCCS)fluorescence life-time imaginginhibitormaturationnsp5precursorproteasevirus

Substanzen

Coronavirus 3C Proteases3C-like proteinase, SARS-CoV-2Protease InhibitorsAntiviral Agents

Autor:innen und Institutionen

  • Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic; Faculty of Science, Department of Physical and Macromolecular Chemistry, Charles University in Prague, Prague, Cz…
  • Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic.
  • Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic; Faculty of Science, Department of Genetics and Microbiology, Charles University in Prague, Prague, Czech Republic.
  • Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic; Department of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Prague, Czech Republi…
  • Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic; Faculty of Science, Department of Biochemistry, Charles University in Prague, Prague, Czech Republic.
  • Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic. Electronic address: tatana.majerova@uochb.cas.cz.

Zitieren

APA

Novotný, P., Humpolíčková, J., Nováková, V., Stanchev, S., Stříšovský, K., Zgarbová, M., Weber, J., Kryštůfek, R., Starková, J., Hradilek, M., Moravcová, A., Günterová, J., Bach, K., Majer, P., Konvalinka, J., & Majerová, T. (2025). The zymogenic form of SARS-CoV-2 main protease: A discrete target for drug discovery. Journal of Biological Chemistry, 301(1), 108079. https://doi.org/10.1016/j.jbc.2024.108079

Vancouver

Novotný P, Humpolíčková J, Nováková V, Stanchev S, Stříšovský K, Zgarbová M, et al. The zymogenic form of SARS-CoV-2 main protease: A discrete target for drug discovery. Journal of Biological Chemistry. 2025;301(1):108079. doi:10.1016/j.jbc.2024.108079

BibTeX
@article{Novotn2025,
  author = {Novotný, Pavel and Humpolíčková, Jana and Nováková, Veronika and Stanchev, Stancho and Stříšovský, Kvido and Zgarbová, Michala and Weber, Jan and Kryštůfek, Robin and Starková, Jana and Hradilek, Martin and Moravcová, Adéla and Günterová, Jana and Bach, Kathrin and Majer, Pavel and Konvalinka, Jan and Majerová, Taťána},
  title = {The zymogenic form of SARS-CoV-2 main protease: A discrete target for drug discovery},
  journal = {Journal of Biological Chemistry},
  year = {2025},
  volume = {301},
  number = {1},
  pages = {108079},
  doi = {10.1016/j.jbc.2024.108079}
}
Kostenlos starten →